You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
High speed Intraoperative Assessment of Breast Tumor Margin using MarginPAT
SBC: Vibronix, Inc. Topic: OAfter a breast conserving therapy histology is often performed to check whether the excised tumor specimen is surrounded by a sufficient amount of normal tissue If a positive margin is identified then a second operation will be performed Currently the re operation rate is which raises a need for intraoperative detection of residual cancers The current intraoperative tools for margin ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
improving Cas9 mediated homologous recombination in pluripotent stem cells
SBC: APPLIED STEMCELL, INC. Topic: 200DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy
SBC: MICROBIOTIX, INC. Topic: NIAIDHuman respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Intra procedure Deformable Ultrasound MRI Fusion for Prostate Biopsies
SBC: ZMK Medical Technologies, Inc. Topic: 102This Phase II proposal is a continuation of our successful Phase I grant whose overarching goal is to develop a more robust and accurate method for the deformable fusion of pre operative magnetic resonance images MRI and intra procedure trans rectal ultrasound TRUS images to guide prostate biopsy Prostate cancer is a major cause of death in the U S and biopsy is the gold standard for its dia ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain
SBC: On Target Therapeutics, LLC Topic: 106DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
SBC: SignalRx Pharmaceuticals Inc. Topic: NCIPARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD
SBC: VIROGENICS, INC. Topic: NIAIDDESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Nanoliter electron paramagnetic resonance sensor based on diamond nanophotonics: a new tool for biomarker monitoring
SBC: ODMR Technologies, Inc Topic: 400DESCRIPTION provided by applicant ODMR Technologies Inc together with Victor Acostaandapos s group at University of New Mexico is developing a nanophotonic platform capable of uniquely detecting minute quantities of biomolecules The specific detection of biomolecules plays a central role in modern life science including cell systems biology high throughput drug scre ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids
SBC: GINER INC Topic: NICHDDESCRIPTION provided by applicant Non Invasive Highly Specific Detection of Oxytocin in Biological Fluids Oxytocin a neuropeptide hormone plays an important role in a variety of complex social behaviors including affiliation sexual behavior and aggression It is best known for its role to facilitate the birth process through induction of myometrial muscle contractions However recent studi ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel therapies for inherited muscle diseases
SBC: Medosome Biotec, LLC Topic: NIAMSDESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health